The study of dapagliflozin (sodium glucose cotransporter 2 inhibitor) to verify the efficacy of combination therapy in Japanese patients with type 2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000015369
- Lead Sponsor
- Okayama University Hospital nephrology, diabates and endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) type 1 diabetes 2) BMI: >= 45 3) patients suspected of pregnancy or pregnant or nursing 4) diabetes insipidus 5) severe liver dysfunction (liver cirrhosis, viral hepatitis, AST: >= 3 times of upper limit) 6) moderate renal dysfunction (eGFR: < 45 ml/min/1.73m2) 7) heart disease (myocardial infarction, unstable angina) or stroke within 3 months 8) considered as inadequate by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change and percent change in HbA1c from baseline to 6 months Adverse events
- Secondary Outcome Measures
Name Time Method